Organon (OGN) Cash & Equivalents (2020 - 2026)

Organon (OGN) has reported Cash & Equivalents for 7 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 104.02% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 104.02% YoY), while the FY2025 annual figure was $574.0 million, down 14.96% from the prior year.
• Cash & Equivalents came in at $1.1 billion for Q1 2026 at Organon, up from $574.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.1 billion in Q1 2026, with the low at $326.0 million in Q2 2023.
• Average Cash & Equivalents over 5 years is $621.2 million, with a median of $599.0 million recorded in 2025.
• The largest YoY upside for Cash & Equivalents was 392.2% in 2022 against a maximum downside of 50.5% in 2022.
• Year by year, Cash & Equivalents stood at $706.0 million in 2022, then slipped by 1.84% to $693.0 million in 2023, then retreated by 2.6% to $675.0 million in 2024, then declined by 14.96% to $574.0 million in 2025, then jumped by 94.43% to $1.1 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.1 billion, $574.0 million, and $672.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.